Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Papers
Trials
Key Impact
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Background & Research
Kayla M. Teopiz appears as an author on multiple publications focused on ketamine, esketamine, psilocybin, suicidality, sleep, and biomarkers in mood disorders. Her publication record suggests involvement in academic psychiatry research centered on treatment-resistant depression and related outcomes. I could not verify a definitive current faculty title from the available sources, so the affiliation is kept conservative.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →